Analysts’ Weekly Ratings Changes for REGENXBIO (RGNX)

Several brokerages have updated their recommendations and price targets on shares of REGENXBIO (NASDAQ: RGNX) in the last few weeks:

• 3/20/2025 – REGENXBIO had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
• 3/18/2025 – REGENXBIO was given a new $24.00 price target on by analysts at Leerink Partners.
• 3/17/2025 – REGENXBIO had its price target lowered by analysts at HC Wainwright from $36.00 to $34.00. They now have a “buy” rating on the stock.
• 3/14/2025 – REGENXBIO had its price target raised by analysts at Morgan Stanley from $22.00 to $24.00. They now have an “overweight” rating on the stock.
• 3/14/2025 – REGENXBIO had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
• 3/7/2025 – REGENXBIO was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 2/25/2025 – REGENXBIO was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 2/15/2025 – REGENXBIO was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 2/11/2025 – REGENXBIO was downgraded by analysts at The Goldman Sachs Group, Inc. from a “buy” rating to a “neutral” rating. They now have a $14.00 price target on the stock, down previously from $38.00.
• 2/7/2025 – REGENXBIO is now covered by analysts at Raymond James. They set an “outperform” rating and a $27.00 price target on the stock.
• 2/7/2025 – REGENXBIO was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 2/6/2025 – REGENXBIO was upgraded by analysts at Raymond James to a “moderate buy” rating.

REGENXBIO Stock Up 4.3 %

Shares of REGENXBIO stock opened at $7.05 on Thursday. The firm has a market capitalization of $353.11 million, a P/E ratio of -1.40 and a beta of 1.26. REGENXBIO Inc. has a 52 week low of $5.62 and a 52 week high of $20.77. The company has a 50 day moving average price of $7.36 and a 200 day moving average price of $8.65.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.26. The company had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. As a group, research analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

Institutional Trading of REGENXBIO

A number of hedge funds have recently modified their holdings of RGNX. GAMMA Investing LLC grew its position in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 2,510 shares during the period. FMR LLC grew its position in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,656 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of REGENXBIO in the 4th quarter valued at about $54,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of REGENXBIO in the 4th quarter valued at about $79,000. Finally, Laurion Capital Management LP acquired a new position in REGENXBIO in the 4th quarter worth about $79,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.